First Time Loading...

Altamira Therapeutics Ltd
NASDAQ:CYTO

Watchlist Manager
Altamira Therapeutics Ltd Logo
Altamira Therapeutics Ltd
NASDAQ:CYTO
Watchlist
Price: 1.5 USD 2.04% Market Closed
Updated: May 10, 2024

Altamira Therapeutics Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Altamira Therapeutics Ltd
Cash from Financing Activities Peer Comparison

Comparables:
NOVN
NLSP
ROG
S
SDZ

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Altamira Therapeutics Ltd
NASDAQ:CYTO
Cash from Financing Activities
CHf10.6m
CAGR 3-Years
-14%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Novartis AG
SIX:NOVN
Cash from Financing Activities
-$10.2B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
-1%
NLS Pharmaceutics AG
NASDAQ:NLSP
Cash from Financing Activities
$17.4m
CAGR 3-Years
249%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Roche Holding AG
SIX:ROG
Cash from Financing Activities
-CHf4.2B
CAGR 3-Years
24%
CAGR 5-Years
17%
CAGR 10-Years
12%
S
Sandoz Group AG
SIX:SDZ
Cash from Financing Activities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Altamira Therapeutics Ltd's Cash from Financing Activities?
Cash from Financing Activities
10.6m CHF

Based on the financial report for Dec 31, 2023, Altamira Therapeutics Ltd's Cash from Financing Activities amounts to 10.6m CHF.

What is Altamira Therapeutics Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
13%

Over the last year, the Cash from Financing Activities growth was 8%. The average annual Cash from Financing Activities growth rates for Altamira Therapeutics Ltd have been -14% over the past three years , 13% over the past five years .